Table 2.

Effects of Anti-dementia drug use on costs by drug class

	Anti-dementia Drugs				ChEIs				NMDAR Antagonist (Memantine)
	Costs Changing ($)	95% CI		P value	Costs Changing ($)	95% CI		P value	Costs Changing ($)	95% CI		P value
Total Costs	−1,612.07	−4,668.72	1,444.59	0.301	−2,385.62	−5,578.66	807.41	0.143	1,644.27	−2,722.50	6,011.04	0.461
Medicare Costs	−4,804.26	−6,904.09	−2,704.44	< 0.001	−5,267.62	−7,434.26	−3,100.98	< 0.001	−3,216.34	−6,447.73	15.04	0.051
OOP Costs	−36.63	−1,455.29	1,382.04	0.960	−458.08	−1,917.07	1,000.92	0.538	648.58	−1,250.17	2,547.33	0.503
Inpatient Costs	−2,842.48	−4,020.36	−1,664.60	< 0.001	−3,044.49	−4,230.54	−1,858.43	< 0.001	−1,993.62	−4,044.24	57.00	0.057
Outpatient Costs	61.59	−597.83	721.02	0.855	−116.40	−696.44	463.64	0.694	253.75	−779.82	1,287.33	0.630

ChEIs Cholinesterase inhibitors, NMDAR N-methyl-D-aspartate receptors, OOP out-of-pocket